SEC, DOJ subpoena Biogen over Aduhelm launch and foreign business operations
Adding to the multiple investigations into Biogen and its controversial Alzheimer’s drug Aduhelm since its approval, the company revealed
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
